Philips gains FDA clearance for 3T MR solution, 2 applications

Royal Philips announced Tuesday, June 5, that its Ingenia Elition 3.0T MR solution and two clinical applications, Philips Compressed SENSE and 3D APT, have received FDA approval.

According to Philips, these solutions can help clinicians perform MR exams up to 50 percent faster, improve the overall patient experience and provide a more confident diagnosis.

“Together, the Ingenia Elition and our new clinical applications make producing high-quality images fast and easy, enabling prompt diagnosis and setting the stage for effective treatment,” Arjen Radder, global business leader for MR at Philips, said in a prepared statement. “We're receiving a strong positive reaction from our customers as we continue to roll out our all-new Ingenia digital MR portfolio. It's providing healthcare organizations like Hennepin Health with innovative solutions that seamlessly connect data, technology and people to drive the highest quality of care.”

Minneapolis-based Hennepin Healthcare recently installed the Ingenia Elition, representing the first commercial installation of the system in the U.S.

“To deliver fast, consistent and accurate diagnoses, our staff need to be supported with technology that gives them the ability to provide the best patient care, in an efficient and cost-effective way,” Chip Truwit, MD, radiology chair at Hennepin Healthcare, said in the statement. “Philips' Ingenia Elition plays a critical role in elevating the standard of care for our patients in imaging and in improving overall operations in our new imaging center.”

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

The patient, who was being cared for in the ICU, was not accompanied or monitored by nursing staff during his exam, despite being sedated.

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.